Real-world effectiveness and tolerability of sotorasib in patients with KRAS G12C-mutated metastatic non-small cell lung cancer: The IFCT-2102 Lung KG12Ci study.

Date publication

février 2025

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr WESTEEL Virginie , Pr MASCAUX Céline

Tous les auteurs :
Wislez M, Mascaux C, Cadranel J, Thomas QD, Ricordel C, Swalduz A, Pichon E, Veillon R, Gounant V, Rousseau-Bussac G, Madroszyk A, Daniel C, Ravoire M, Metivier AC, Fournel P, Missy P, Morin F, Guisier F, Westeel V

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/39970524

Résumé

Sotorasib has shown efficacy in a phase 3 trial compared to docetaxel among previously treated non-small cell lung cancer (NSCLC) patients with a KRAS G12C mutation. However, its real-world effectiveness and tolerance, especially post-immunotherapy, remain debated.

Mots clés

KRAS inhibitor, KRAS mutation, Non-small-cell lung cancer, Real-world evidence, Sotorasib, Targeted therapy

Référence

Eur J Cancer. 2025 02 11;219:115301